Biologics to treat substance use disorders: Current status and new directions

Traditional treatments for substance use disorders (SUD) typically rely on small-molecule medications that target receptors in the brain to modulate neurotransmitter activity. In contrast, biological therapies (biologics) represent a shift in strategy. Instead of acting on brain receptors, biologics target the drug molecules themselves. By sequestering drugs in the serum through antibodies or chemically degrading them with specific enzymes, these treatments prevent the drug from reaching the central nervous system, thereby blunting its rewarding and addictive effects.

Vaccines for SUD work by stimulating the immune system to produce polyclonal antibodies against a specific drug (e.g., nicotine, cocaine, or opioids). These antibodies act as a molecular filter. While preclinical models have consistently demonstrated that this approach can reduce drug distribution to the brain, human clinical trials have faced difficulties. Most notably, first-generation vaccines for nicotine and cocaine only showed efficacy in a subset of patients—those who managed to produce the highest concentrations of anti-drug antibodies. Current research is focusing on why this individual variability occurs and how to optimize vaccine design to ensure more robust and consistent immune responses.

To move beyond the limitations of early trials, researchers are exploring next-generation vaccine designs. These include using more effective carriers, advanced adjuvants, and particle-based scaffolds to enhance antigen presentation and T-cell help. Furthermore, there is significant interest in using biomarkers—specifically tracking vaccine-specific B and T cell populations—to stratify patients and predict who will benefit most from treatment.

Beyond active vaccination, passive immunization with monoclonal antibodies and the use of genetically engineered enzymes offer alternative, potentially more potent, pathways. The author suggests that these biological tools might eventually be used in combination with each other or with traditional medications, potentially leading to more effective, personalized treatment protocols for people at different stages of addiction.